MCID: SBP001
MIFTS: 47

Subependymal Giant Cell Astrocytoma malady

Rare diseases, Neuronal diseases, Cancer diseases categories

Aliases & Classifications for Subependymal Giant Cell Astrocytoma

About this section
Sources:
8Disease Ontology, 42NIH Rare Diseases, 10DISEASES, 48Orphanet, 61UMLS, 44Novoseek, 56SNOMED-CT, 39NCIt, 33MeSH, 62UMLS via Orphanet
See all sources

Aliases & Descriptions for Subependymal Giant Cell Astrocytoma:

Name: Subependymal Giant Cell Astrocytoma 8 42 10 48 61
Sega 8 42 48
 
Astrocytoma Subependymal Giant Cell 44


Classifications:



External Ids:

Disease Ontology8 DOID:5077
NCIt39 C3696
MeSH33 D001254
SNOMED-CT56 1586004
Orphanet48 251618
UMLS via Orphanet62 C0205768

Summaries for Subependymal Giant Cell Astrocytoma

About this section
Wikipedia:64 Subependymal giant cell astrocytoma (SEGA, SGCA, or SGCT) is a low-grade astrocytic brain tumor... more...

MalaCards based summary: Subependymal Giant Cell Astrocytoma, also known as sega, is related to giant cell glioblastoma and subependymoma. An important gene associated with Subependymal Giant Cell Astrocytoma is FABP7 (fatty acid binding protein 7, brain), and among its related pathways are FSH signaling pathway and Insulin receptor signalling cascade. The compounds reticulin and eosin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and thyroid, and related mouse phenotypes are renal/urinary system and no phenotypic analysis.

Related Diseases for Subependymal Giant Cell Astrocytoma

About this section

Diseases related to Subependymal Giant Cell Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 151)
idRelated DiseaseScoreTop Affiliating Genes
1giant cell glioblastoma31.4GFAP
2subependymoma31.4TSC2
3gemistocytic astrocytoma31.1GFAP, S100B
4angiomyolipoma31.1TSC1, MTOR, TSC2, VIM
5neuroblastoma30.9ENO2, SYP, TP53
6astrocytoma30.7S100B, GFAP, TP53, VIM, NES, TSC2
7central neurocytoma30.7MAP2, SYP, GFAP
8tuberous sclerosis30.6GFAP, VIM, NES, TSC2, TSC1, MTOR
9retinoblastoma29.8MAP2, GFAP, TP53, MTOR, SYP, ENO2
10glioblastoma29.6GFAP, TP53, MAP2, CCK, S100B, MTOR
11gliomatosis cerebri10.6GFAP
12dysembryoplastic neuroepithelial tumor10.6SYP
13melanotic neuroectodermal tumor10.6SYP
14mixed glioma10.6GFAP
15perivascular epithelioid cell tumor10.5TSC2
16alexander disease10.5GFAP
17medulloepithelioma10.5SYP
18somatostatinoma10.5SST
19ewing's family of tumors10.5ENO2
20tuberous sclerosis-110.5TSC2, TSC1
21epulis10.5ENO2
22lymphangioleiomyomatosis10.5TSC2, TSC1
23intestinal disease10.4SST
24pineoblastoma10.4GFAP, SYP
25west syndrome10.4TSC1, TSC2
26binswanger's disease10.4GFAP, SYP
27gliosarcoma10.4GFAP
28cystic kidney10.4TSC1, TSC2
29cowden disease10.4TSC2, TSC1
30syringoma10.4S100B, GFAP
31huntington disease10.4SST, NPY
32gallbladder disease10.4CCK, TSC1
33lymphedema10.4
34thyroiditis10.4
35myxopapillary ependymoma10.4S100B, GFAP
36choroid plexus carcinoma10.4GFAP, S100B
37neurilemmoma10.4GFAP, ENO2
38anaplastic ependymoma10.3GFAP, S100B
39islet cell tumor10.3SYP, SST
40endocrine gland cancer10.3SST, SYP
41von hippel-lindau syndrome10.3NPY, TSC2
42hydrocephalus10.3TSC1, NES
43kidney angiomyolipoma10.3TSC2, MTOR, TSC1
44bulimia nervosa10.3CCK, NPY
45peutz-jeghers syndrome10.3TSC2, TSC1, MTOR
46polycystic kidney disease10.3MTOR, TSC1, TSC2
47polycystic kidney disease, autosomal dominant10.3TSC2, MTOR, TSC1
48temporal lobe epilepsy10.3CALB1, GFAP, NPY
49status epilepticus10.3ENO2, NPY
50rhabdoid meningioma10.3VIM, GFAP

Graphical network of the top 20 diseases related to Subependymal Giant Cell Astrocytoma:



Diseases related to subependymal giant cell astrocytoma

Symptoms for Subependymal Giant Cell Astrocytoma

About this section

Drugs & Therapeutics for Subependymal Giant Cell Astrocytoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.

Drug clinical trials:

Search ClinicalTrials for Subependymal Giant Cell Astrocytoma

Search NIH Clinical Center for Subependymal Giant Cell Astrocytoma

Genetic Tests for Subependymal Giant Cell Astrocytoma

About this section

Anatomical Context for Subependymal Giant Cell Astrocytoma

About this section

MalaCards organs/tissues related to Subependymal Giant Cell Astrocytoma:

31
Brain, Spinal cord, Thyroid, Skin, Testes

Animal Models for Subependymal Giant Cell Astrocytoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Subependymal Giant Cell Astrocytoma:

35 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053678.7TSC1, NPY, TSC2, MTOR, TP53
2MP:00030128.4SST, FABP7, CCK, TP53, SYP, MTOR
3MP:00053808.3MTOR, TSC1, TSC2, NES, TP53, VIM
4MP:00053888.3TSC1, MTOR, TP53, VIM, ENO2
5MP:00053847.6NES, MTOR, TSC1, TSC2, VIM, TP53
6MP:00107687.3MAP2, VIM, MTOR, NES, TSC2, TSC1
7MP:00053767.2SST, GFAP, TP53, VIM, FABP7, TSC2
8MP:00053787.1GFAP, NES, TSC2, TSC1, SST, MTOR
9MP:00028737.1S100B, CALB1, SYP, MTOR, SST, TSC2
10MP:00053865.2MAP2, CALB1, S100B, ENO2, NPY, NES
11MP:00036314.9TP53, NPY, ENO2, GFAP, CALB1, MAP2

Publications for Subependymal Giant Cell Astrocytoma

About this section

Articles related to Subependymal Giant Cell Astrocytoma:

(show top 50)    (show all 122)
idTitleAuthorsYear
1
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma. (25909870)
2015
2
Thyroid transcription factor-1 and epithelial membrane antigen expression in four cases of subependymal giant cell astrocytoma. (25195621)
2014
3
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. (25456370)
2014
4
A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. (24180681)
2014
5
Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex. (25143481)
2014
6
Resection of subependymal giant cell astrocytoma guided by intraoperative magnetic resonance imaging and neuronavigation. (23397586)
2013
7
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. (23391693)
2013
8
Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature. (23138436)
2013
9
Congenital Segmental Lymphedema in Tuberous Sclerosis Complex With Associated Subependymal Giant Cell Astrocytomas Treated with Mammalian Target of Rapamycin Inhibitors. (24056156)
2013
10
Response of Subependymal Giant Cell Astrocytoma With Spinal Cord Metastasis to Everolimus. (24276039)
2013
11
Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. (22805244)
2013
12
Subependymal giant cell astrocytoma with intratumoral hemorrhage. (23414132)
2013
13
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. (24143074)
2013
14
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. (23325902)
2013
15
Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. (23567018)
2013
16
Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. (22375958)
2012
17
Subependymal giant cell astrocytoma: Cytological findings. (23326038)
2012
18
Squash cytology of subependymal giant cell astrocytoma: report of four cases with brief review of literature. (22431322)
2012
19
Everolimus tablets for patients with subependymal giant cell astrocytoma. (21806479)
2011
20
Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. (21415462)
2011
21
Bulky subependymal giant cell astrocytoma with profuse blood supply without tuberous sclerosis. (20956931)
2010
22
Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. (20887114)
2010
23
Neonatal subependymal giant cell astrocytoma: new case and review of literature. (17275668)
2007
24
Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. (17071037)
2007
25
Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. (17536538)
2007
26
Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. (15851742)
2005
27
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. (15624760)
2004
28
Subependymal giant cell astrocytoma with positive tuberin expression--case report. (14723270)
2003
29
Rapid regrowth of solitary subependymal giant cell astrocytoma--case report. (12064158)
2002
30
Secondary parathyroid hyperplasia in tuberous sclerosis: report of a case with large eosinophilic ganglion-like cells similar to those of subependymal giant cell astrocytoma, tubers, and atypical angiomyolipoma. (11812950)
2002
31
Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases. (11322123)
2001
32
Subependymal giant cell astrocytoma associated with tuberous sclerosis exhibiting rapid regrowth after 17 years: a case report]. (10396738)
1999
33
Image interpretation session: 1998. Tuberous sclerosis with multiple bilateral renal cysts and a subependymal giant cell astrocytoma. (10722364)
1999
34
Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. (9568761)
1998
35
Subependymal giant-cell astrocytoma associated with tuberous sclerosis: case report. (9795959)
1998
36
Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. (9403714)
1997
37
Immunohistochemical characterization of subependymal giant cell astrocytomas. (8928613)
1996
38
Hemorrhagic subependymal giant cell astrocytoma. (7761172)
1995
39
A neonatal huge subependymal giant cell astrocytoma: case report. (7808622)
1994
40
Cytomorphology of subependymal giant cell astrocytoma. A case report. (8465641)
1993
41
The cystic growth of a subependymal giant-cell astrocytoma with tuberous sclerosis. (1405432)
1992
42
Tuberous sclerosis complex: oligosymptomatic variant associated with subependymal giant-cell astrocytoma. (1749677)
1991
43
Clinical and immunohistochemical studies of subependymal giant cell astrocytomas associated with tuberous sclerosis. (1705105)
1990
44
Rare subependymal giant-cell astrocytoma in a neonate with tuberous sclerosis. (2124070)
1990
45
Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? (2702677)
1989
46
Subependymal giant-cell astrocytoma in children. An unusual discrepancy between histological and clinical features. (3286833)
1988
47
Subependymal giant-cell astrocytoma. A case report. (3218563)
1988
48
Paratesticular neuroblastoma associated with subependymal giant cell astrocytoma. (7452809)
1980
49
Subependymal giant-cell astrocytoma. Case report with ultrastructural study. (430139)
1979
50
Recurrent subependymal giant-cell astrocytoma in the absence of tuberous sclerosis. Case report. (758371)
1979

Variations for Subependymal Giant Cell Astrocytoma

About this section

Expression for genes affiliated with Subependymal Giant Cell Astrocytoma

About this section
Search GEO for disease gene expression data for Subependymal Giant Cell Astrocytoma.

Pathways for genes affiliated with Subependymal Giant Cell Astrocytoma

About this section

Pathways related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 23)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.9TSC2, MTOR
2
Show member pathways
9.7MTOR, TSC2, TSC1
3
Show member pathways
mTOR signaling pathway36
9.7TSC2, MTOR, TSC1
49.7MTOR, TSC1, TSC2
59.7TSC2, TSC1, MTOR
69.4TSC1, TSC2, TP53
7
Show member pathways
Signal transduction PTEN pathway59
9.3MTOR, TSC2, TP53
89.3MTOR, TSC2, TP53
9
Show member pathways
9.2TSC2, S100B, GFAP, MTOR
109.1VIM, TP53, GFAP
11
Show member pathways
Signaling Pathways in Glioblastoma36
9.0TSC2, TSC1, MTOR, TP53
129.0TP53, TSC2, TSC1, MTOR
139.0TP53, TSC2, TSC1, MTOR
149.0TP53, TSC2, TSC1, MTOR
15
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.0TP53, TSC2, MTOR, TSC1
16
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.0MTOR, TSC1, TSC2, TP53
179.0MTOR, TP53, TSC2, TSC1
18
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
9.0MAP2, MTOR, TP53
19
Show member pathways
8.6TP53, GFAP, TSC1, VIM, TSC2
208.5TSC2, TSC1, MTOR, MAP2, TP53
21
Show member pathways
7.4TSC2, TSC1, GFAP, SST, CCK, MTOR
227.1CALB1, GFAP, SYP, MAP2, S100B, ENO2

Compounds for genes affiliated with Subependymal Giant Cell Astrocytoma

About this section

Compounds related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 159)
idCompoundScoreTop Affiliating Genes
1reticulin449.4GFAP, VIM, SYP, S100B
2eosin449.4S100B, GFAP, VIM
3spec-t449.3ENO2, SST, TSC1, GFAP
4n-acetylaspartate449.2GFAP, SYP, CALB1
5streptozotocin449.0SYP, NES, VIM, GFAP, SST, NPY
6s 100448.9GFAP, VIM, SYP, S100B, ENO2
7catecholamine448.7VIM, SYP, ENO2, NPY, S100B
8ganglioside448.6SYP, ENO2, GFAP, VIM, NES, MAP2
9vinblastine44 50 1110.5MAP2, SST, VIM, TP53, NPY
10tetrodotoxin44 60 2810.5CALB1, GFAP, CCK, ENO2, NPY
11cocaine44 119.5VIM, CCK, MAP2, NPY, S100B, GFAP
12methamphetamine44 50 1110.5CALB1, GFAP, MAP2, NPY
13kainate44 289.4NPY, GFAP, NES, SYP, MAP2, CALB1
14hematoxylin448.4S100B, MAP2, SYP, VIM, GFAP, ENO2
15dbc-amp448.4ENO2, S100B, MAP2, SYP, VIM, GFAP
16acth448.4S100B, GFAP, CCK, SYP, ENO2, NPY
17silver448.3SYP, ENO2, GFAP, CALB1, MAP2
18l-amino acid448.3SYP, S100B, ENO2, MAP2, CALB1
19leucine448.2SYP, ENO2, S100B, MTOR, TSC2, VIM
20glutamine448.2S100B, GFAP, VIM, CCK, SYP, ENO2
21dmso448.2NES, NPY, ENO2, VIM, MAP2
22lactate448.0ENO2, NPY, SST, S100B, GFAP, VIM
23formaldehyde44 248.8NPY, CALB1, SYP, GFAP, VIM, ENO2
24potassium44 24 119.8ENO2, CALB1, MAP2, GFAP, SYP, S100B
25lipid447.7MTOR, NES, ENO2, GFAP, TSC2, SYP
26nmda44 288.7SYP, ENO2, NPY, CALB1, MAP2, VIM
27bromodeoxyuridine447.7S100B, ENO2, CALB1, NES, VIM, GFAP
28glycogen44 248.6SYP, MTOR, TSC1, TSC2, VIM, GFAP
295-hydroxytryptamine447.5SST, CCK, GFAP, NPY, ENO2, CALB1
30arginine447.5MTOR, CCK, S100B, TP53, GFAP, VIM
31progesterone44 28 60 24 1111.5VIM, GFAP, ENO2, S100B, MAP2, SYP
32adenylate447.4SST, NPY, S100B, GFAP, VIM, MAP2
33forskolin44 50 119.4GFAP, VIM, NPY, ENO2, S100B, CALB1
34nitric oxide44 24 119.4NES, NPY, MAP2, CALB1, S100B, SYP
35norepinephrine44 24 119.3ENO2, MAP2, SYP, CCK, NPY, CALB1
36serine447.2VIM, TSC2, S100B, TP53, GFAP, MAP2
37dexamethasone44 50 28 1110.0MTOR, SYP, VIM, CALB1, S100B, ENO2
38atp44 287.9NPY, ENO2, CALB1, MTOR, VIM, GFAP
39acetylcholine44 50 28 24 1110.9SST, CCK, NES, VIM, GFAP, NPY
40dopamine44 28 24 119.8S100B, CCK, NPY, GFAP, NES, SST
41paraffin446.8NPY, ENO2, S100B, MAP2, SYP, TSC1
42choline44 24 118.8S100B, ENO2, NPY, CALB1, MAP2, SYP
43vegf446.4ENO2, S100B, MAP2, SYP, MTOR, SST
44tyrosine446.3ENO2, TSC1, NPY, S100B, CALB1, CCK
45glucose446.3GFAP, NES, TSC2, TSC1, SST, CCK
46glutamate446.2NPY, ENO2, S100B, CALB1, MAP2, SYP
47gaba446.2SYP, MAP2, CALB1, S100B, ENO2, NPY
48testosterone44 60 24 119.0S100B, CALB1, MAP2, SYP, MTOR, CCK
49estrogen445.9NPY, ENO2, S100B, CALB1, MAP2, SYP
50retinoic acid44 246.2S100B, CALB1, MAP2, SYP, MTOR, CCK

GO Terms for genes affiliated with Subependymal Giant Cell Astrocytoma

About this section

Cellular components related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.0TSC2, TSC1
2intermediate filamentGO:00058829.2GFAP, VIM, NES
3extracellular spaceGO:00056158.5NPY, ENO2, S100B, CCK, SST
4neuronal cell bodyGO:00430258.0S100B, FABP7, TSC2, SST, MAP2, CALB1
5cytoplasmGO:00057377.0GFAP, TP53, VIM, NES, FABP7, TSC2
6cytosolGO:00058296.9GFAP, TP53, VIM, TSC2, TSC1, MTOR

Biological processes related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of TOR signalingGO:003200710.1TSC1, TSC2
2Bergmann glial cell differentiationGO:006002010.1VIM, GFAP
3astrocyte developmentGO:001400210.0VIM, GFAP
4intermediate filament organizationGO:004510910.0GFAP, VIM
5negative regulation of cell sizeGO:004579210.0MTOR, TSC1, TSC2
6regulation of protein kinase activityGO:004585910.0MTOR, TSC1
7regulation of neuronal synaptic plasticityGO:004816810.0S100B, SYP
8central nervous system neuron developmentGO:00219549.9MAP2, NPY
9long-term synaptic potentiationGO:00602919.8GFAP, S100B
10insulin receptor signaling pathwayGO:00082869.8TSC2, TSC1, MTOR
11negative regulation of neuron projection developmentGO:00109779.8VIM, GFAP
12positive regulation of protein oligomerizationGO:00324619.7CCK, TP53
13cell cycle arrestGO:00070509.5TSC1, TSC2, TP53
14response to amino acidGO:00432009.5MTOR, SST
15axonogenesisGO:00074099.5S100B, MAP2, CCK
16positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.5TP53, CCK, MTOR
17central nervous system developmentGO:00074179.4S100B, NES, TP53
18cellular response to hypoxiaGO:00714569.4TP53, MTOR, S100B
19release of cytochrome c from mitochondriaGO:00018369.4CCK, TP53
20cellular response to organic substanceGO:00713109.2CALB1, MAP2, SYP
21negative regulation of cell proliferationGO:00082859.1TP53, FABP7, TSC2, TSC1, SST

Molecular functions related to Subependymal Giant Cell Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuropeptide hormone activityGO:00051849.8NPY, CCK
2identical protein bindingGO:00428028.4S100B, SYP, VIM, TP53

Sources for Subependymal Giant Cell Astrocytoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet